Mostrar el registro sencillo del ítem
Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China
dc.contributor.author | Li, Bo | |
dc.contributor.author | Yang, Jing | |
dc.contributor.author | Zhao, Faming | |
dc.contributor.author | Zhi, Lili | |
dc.contributor.author | Wang, Xiqian | |
dc.contributor.author | Liu, Lin | |
dc.contributor.author | Bi, Zhaohui | |
dc.contributor.author | Zhao, Yunhe | |
dc.date.accessioned | 2020-04-01T20:17:56Z | |
dc.date.available | 2020-04-01T20:17:56Z | |
dc.date.issued | 2020-03-11 | |
dc.identifier.uri | https://doi.org/10.1007/s00392-020-01626-9 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/896 | |
dc.description.abstract | [Abstract]. Background: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19. Methods: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies. Results: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients. Conclusion: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Diabetes Mellitus | en_US |
dc.subject | Hypertension | en_US |
dc.subject | Cerebrovascular Disorders | en_US |
dc.title | Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China | en_US |
eihealth.country | Others | en_US |
eihealth.category | Clinical characterization and management | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |